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Supporting anticoagulant treatment
decision making to optimise stroke
prevention in complex patients with atrial
fibrillation: a cluster randomised trial
Melina Gattellari1,2*, Andrew Hayen3, Dominic Y. C. Leung4,5, Nicholas A. Zwar6 and John M. Worthington1,4
Abstract
Background: Anticoagulation for preventing stroke in atrial fibrillation is under-utilised despite evidence supporting
its use, resulting in avoidable death and disability. We aimed to evaluate an intervention to improve the uptake of
anticoagulation.
Methods: We carried out a national, cluster randomised controlled trial in the Australian primary health care
setting. General practitioners received an educational session, delivered via telephone by a medical peer and
provided information about their patients selected either because they were not receiving anticoagulation or for
whom anticoagulation was considered challenging. General practitioners were randomised to receive feedback
from a medical specialist about the cases (expert decisional support) either before or after completing a post-test
audit. The primary outcome was the proportion of patients reported as receiving oral anticoagulation. A secondary
outcome assessed antithrombotic treatment as appropriate against guideline recommendations.
Results: One hundred and seventy-nine general practitioners participated in the trial, contributing information
about 590 cases. At post-test, 152 general practitioners (84.9%) completed data collection on 497 cases (84.2%). A
4.6% (Adjusted Relative Risk = 1.11, 95% CI = 0.86–1.43) difference in the post-test utilization of anticoagulation
between groups was not statistically significant (p = 0.42). Sixty-one percent of patients in both groups received
appropriate antithrombotic management according to evidence-based guidelines at post-test (Adjusted Relative
Risk = 1.0; 95% CI = 0.85 to 1.19) (p = 0.97).
Conclusions: Specialist feed-back in addition to an educational session did not increase the uptake of
anticoagulation in patients with AF.
Trial registration: ANZCTRN12611000076976 Retrospectively registered.
Keywords: Atrial fibrillation, Knowledge translation, Stroke prevention
Background
Affecting 1 in 20 people over the age of 65 and one in
10 people older than 75 years [1], atrial fibrillation (AF)
is associated with a five-fold increased risk of ischaemic
stroke [2]. AF-related strokes are more likely to be fatal
and disabling than those occurring in patients without
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AF [3], representing a significant burden for individuals,
their families and the wider the community.
The long-standing evidence-practice gap in AF man-
agement is widely documented [4–10]. Evidence from
randomised controlled trials confirms anticoagulation as
the most effective antithrombotic to prevent stroke in
AF [11]. However, at least one-half of people with AF do
not receive anticoagulation and up to 85% experiencing
an acute ischaemic stroke are either not anticoagulated
or have sub-therapeutic anticoagulation [5, 7, 8].
General practitioners (GPs) have considerable reser-
vations about prescribing anticoagulants, appearing to
be “more influenced by the events they induce (bleeds)
than the events potentially prevented, in this case dev-
astating strokes” [12]. However, the benefits of antic-
oagulation outweigh the risks for the majority of
people with AF, including for those with elevated
bleeding risks such as the elderly [4–10]. Only around
2% of people with AF have an absolute contraindica-
tion to oral anticoagulants [10].
Barriers to evidence-based management must be
overcome to minimise stroke risk. Implementation
strategies such as academic detailing and audit and
feedback may increase evidence-based practices [13,
14]. Opinion led educational programs may also effect
change in patient management [15]. At the time of
designing the study reported here, to our knowledge,
there were only two randomised evaluations of imple-
mentation strategies designed to promote anticoagu-
lant prescribing specifically targeting GPs. Ornstein
et al. [16] implemented quarterly audit and written
feedback reports about the management of several
conditions, including AF, randomising 10 out of 20
practices to receive educational site visits and inter-
practice meetings to share approaches to improve pa-
tient management. Changes in anticoagulant prescrib-
ing did not significantly differ between study arms.
Audit and feedback reports presented the percentage
of anticoagulated AF patients and were not focussed
on individual patient cases for which tailored and
specific advice may be necessary to overcome barriers
to anticoagulant prescribing. Several stroke risk fac-
tors were simultaneously targeted, which may have
displaced attention from managing AF to arguably
less challenging care, such as blood pressure, glucose
and lipid level monitoring, which were successfully
modified. In another trial, a multifaceted intervention
including an educational outreach visit increased AF
case-finding but not appropriate antithrombotic pre-
scribing [17]. The effect on anticoagulant prescribing
was not reported. In Australia, a non-randomised
study found that guideline dissemination and educa-
tional outreach targeting GPs increased warfarin use
demonstrating the promise of these strategies [18].
Specialist opinions about how to best manage AF may
be highly influential, guiding GP decision-making. In
everyday practice there are limited opportunities for GPs
to liaise with specialists for educational purposes. In one
randomised controlled trial of stroke survivors, including
32 patients with AF, a model encouraging shared care
between discharging specialists and GPs mediated by a
nurse educator improved stroke risk management [19].
We therefore conducted a randomised controlled trial
of an intervention targeting barriers to anticoagulation
prescribing. We evaluated the impact of specialist com-
munication about stroke prevention exclusively in AF,
providing GPs with the opportunity to discuss specific
patient cases and barriers to management with a medical
peer, followed by expert decisional support to consoli-
date decision making. We hypothesised that a signifi-
cantly higher proportion of cases managed by GPs
provided with expert decisional support would receive
anticoagulation compared with cases whose GPs re-
ceived academic detailing in the form of an educational
session alone.
Methods
The study protocol has been published [20] and
methods are summarised here. The study adheres to
consort criteria for the reporting of cluster randomised
controlled trials. The study was conducted between 2010
to 2012, incorporating GP recruitment commencing in
2010 and final post-test data collection in 2012.
Setting
Almost 90% (88.6%) of the full-time equivalent Austra-
lian GP workforce is in private practice [21] and around
85% of Australian residents consult a GP at least once a
year [22]. Private practice encompasses primary care as-
sessments, preventive medicine, the ongoing care of pa-
tients with chronic illness, care of minor acute illness,
hospital referrals and access to specialist and diagnostic
services. Residents can consult any GP of their choosing
irrespective of residential location. Consultation costs
are subsidised by Australia’s universal health insurance
scheme.
Participant recruitment
As described elsewhere [20], a random sample of GPs
from across Australia was selected and approached by
mail. GPs participating in another study conducted by
the authors were not contacted. We first undertook a
pilot of recruitment methods to inform the number of
GPs we needed to contact to achieve the required sam-
ple size. This was followed by two phases of recruitment
(2010 and 2011), during which we carried out two trials
of response-aiding strategies [20], the results of which
will be reported elsewhere. GPs were asked to register
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their interest in the program and those so doing were
mailed further information and a consent form. Trainee
GPs and GPs who indicated that they were not in active
private practice or whose practice did not include elderly
patients were considered ineligible.
Consenting doctors received written educational mate-
rials followed by an educational session, delivered via tele-
phone by a medically trained peer, also a GP. The
educational session was consistent with academic detailing
as the session was designed to be interactive, with peers de-
tailing the mailed educational materials with the GP partici-
pants. The GP peers reinforced appropriate practice and
conveyed evidence-based information to address practice
that was not consistent with recommended management.
We use the term “academic detailing” to label the inter-
active one-to-one educational component of the program
and this term is used from here on.
The content of the educational materials, reported in
our protocol [20], was mirrored during the academic de-
tailing session to reinforce messages. Briefly, medical
peers discussed the epidemiology of AF and stroke out-
comes of AF-related stroke, risk calculation of stroke
and expected risk reduction associated with anticoagula-
tion and antiplatelet medication. Stroke risk was calcu-
lated using the CHADS2 score (one point each for
Congestive Heart Disease, Hypertension and Age over
75 and two points allocated for prior history of stroke or
transient ischaemic attack) [23] with scores ranging from
0 for patients without any CHADS2 risk factors to 6 for
those with all CHADS2 comorbidities. Both medical
peers and GP participants had access to a table reporting
baseline stroke risk per 1000 patient years for each value
of the CHADS2 score based on those reported by Gage,
Waterman, Shannon et al. [23]. The absolute risk with
either warfarin or aspirin was presented to GPs calcu-
lated by applying an estimated benefit of a 67% relative
risk reduction for warfarin and a 21% relative risk reduc-
tion for aspirin [24]. For example, a CHADS2 risk score
of 3 corresponds to an absolute annual risk of stroke of
5.9%, reduced by 67% and 21% in relative terms to 1.9%
with warfarin and 4.7% with aspirin, respectively.
To explore barriers, GPs were asked how many out of
10 patients with AF over the age of 65 they would anti-
coagulant. Medical peers asked GPs what would charac-
terise patients not receiving anticoagulation and then
systematically addressed reasons offered against anticoa-
gulation. Information predominately pertained to warfarin
as the only government subsidised anticoagulant available
for managing AF during the course of the study.
Pre-test data collection informing primary and secondary
outcomes
During the academic detailing session, GPs provided de-
tails about their selected AF cases, including age, sex,
type of AF (paroxysmal versus chronic) and stroke risk
factors to enable calculation of the CHADS2 score [23].
History and current use of antithrombotic medication
were also determined. Medical history relating to actual
or perceived barriers to anticoagulation were reported.
We advised GPs to identify 3 to 4 AF patients during
the first and at least five patients during the second
phase of recruitment who were not receiving anticoagu-
lation or for whom management was challenging. There-
fore, the intervention was designed to support GP
decision-making where decisions to prescribe anticoagu-
lation was perceived to be complex or uncertain thus
identifying patient cases in whom barriers to anticoagu-
lation would be encountered. Medical peers and GPs
discussed relevant guideline recommendations for either
anticoagulation or antiplatelet medication based on
stroke risk and the American Chest Physician Guidelines
current at the time the study was conducted [25]. Safety
issues were addressed including combination antithrom-
botic treatment, effect of hypertension on stroke risk,
anticoagulant use in patients with a history of intracere-
bral haemorrhage and regulatory authority safety alerts
for direct oral anticoagulants (DOACs), where applic-
able. GPs were then given the opportunity to pose ques-
tions to be answered by specialists.
Randomization and allocation concealment
Academic detailers noted the date and time of the aca-
demic detailing session indicating entry into the study.
GPs were ordered according to their entry into the study
and randomised by a statistician independent to the re-
search team to either receive expert decisional support
or to academic detailing alone, receiving decisional sup-
port after the post-test phase was completed. Block
randomization was stratified according to the number of
cases per GP (≤ 2 or > 3), using a block size of two, four
or six, with block size randomly varied.
Expert decisional support intervention
Information completed during academic detailing ses-
sions was entered into an excel spreadsheet, populated
into a one to two-page document and forwarded to ex-
perts by the first author. Specialists in neurology, cardi-
ology or geriatric medicine provided written feedback,
commenting on existing risk management and providing
recommendations for antithrombotic treatment. A hypo-
thetical example of summaries mailed to GPs has been
published [20] and is reproduced here (Fig. 1).
Academic detailing only group
GPs randomised to receive academic detailing only were
mailed a summary of the proforma without expert spe-
cialist feedback. Proformas included a summary of the
patient’s risk of ischaemic stroke and safety messages
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were re-stated, where relevant (also included on the
summary for GPs allocated to expert decisional
support).
Post-test data collection and outcomes
Post-test assessment was scheduled within 12 weeks of
the delivery of expert decisional support or patient sum-
maries for GPs allocated to the academic detailing only
arm.
The primary outcome was the proportion of cases re-
corded by GPs at post-test as currently receiving anti-
coagulant treatment, either with warfarin, clexane or
dabigatran, the only DOAC first made available for man-
aging AF in Australia from June 2011 through an indus-
try funded familiarisation program. We selected
anticoagulation as the primary outcome as barriers to
the wider use of warfarin were predominately targeted
given the evidence-based gap in managing AF related to
concerns about anticoagulation and not antiplatelet use
[7, 9, 10]. This outcome was also considered robust
against reporting bias as treatment is readily ascertained
by prescription records.
Secondary endpoints included antithrombotic treat-
ment defined as appropriate if receiving 1) aspirin, 2) ei-
ther an anticoagulant or antiplatelet, or 3) an
anticoagulant if their baseline CHADS2 scores were 0, 1,
or 2+, respectively, according to evidence-based guide-
lines current at the time of the study [25]. As an add-
itional secondary outcome, we qualified the above
definition of “appropriate” antithrombotic treatment for
Fig. 1 Expert summary delivered to GPs enrolled in the STOP-STROKE in AF study, 2010–2012. While this information is based on a real patient,
demographic and disease characteristics have been modified to derive this hypothetical patient case. First published in Gattellari M, Worthington
JM, Leung DY, Zwar. Supporting treatment decision making to optimise the prevention of stroke in atrial fibrillation: the STOP STROKE in AF
study. Protocol for a cluster randomised controlled trial. Implementation Science, 2012; 7:63 https://doi.org/10.1186/1748-5908-7-63 Creative
Commons Attribution License 4.0
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patients receiving warfarin if their six most recent INR
results indicated at least monthly assessment and at least
four were within therapeutic range (ie, within 2.0–3.0)
[26, 27]. Patients younger than 65 years of age were ex-
cluded from the analysis of these secondary endpoints as
pre-specified in our protocol [20] because the CHADS2
score was validated in patients aged over the age of 65
years.
“Appropriate” antithrombotic treatment was assessed
using CHADS2 risk factors ascertained at baseline as the
assessment and recording of these comorbidities during
the course of the trial could have been influenced by the
intervention itself potentially leading to differential as-
certainment between groups. As we could not independ-
ently assess stroke risk factors at post-test, this outcome
was designated a secondary outcome. Thus, CHADS2
comorbidities were recorded prior to randomisation to
avoid biased ascertainment.
During the course of the study, validation of the
CHA2DS2-VASc score [28] was published at which point
we incorporated this information into the education pro-
gram. To ensure consistency across all cases, however,
we used the CHADS2 score for outcome ascertainment
as per the original protocol.
Levels of decisional conflict about warfarin were mea-
sured using a five-item scale [29], adapted by specifying
warfarin and/or its prescription within each statement.
For each patient, GPs indicated their level of agreement
to six statements to assess the extent to which GPs had
reservations about prescribing warfarin for the patient.
Summed item scores ranged from 6 to 30 with higher
scores indicating a greater degree of uncertainty about
whether or not to prescribe warfarin.
Sample size estimate
We required a total of 340 patients in total to detect a
15% difference in the primary outcome, assuming a 50%
baseline rate of anticoagulant prescribing [30]. This esti-
mate was multiplied by a design effect of 1.06, account-
ing for the clustered data, assuming an intraclass
correlation coefficient of 0.029 [27], and, to produce an
anticonservative estimate for the required number of
GPs, an average of three patients per GP. We inflated
the total sample size of 361 patients (1.06 × 340 = 361)
by 20% to adjust for losses to follow-up, producing a
final estimate of 452 patient cases (226 per group) and
152 GPs (76 per group).
Statistical analysis
Analyses were carried out by a biostatistician (co-author
Andrew Hayen) blinded to group allocation. The ana-
lyses were intention-to-treat with patient data analysed
according to group allocation. Log-binomial models
were fitted to obtain relative risks for the analysis of
dichotomous outcomes, while differences in decisional
conflict scores were analysed using multiple linear re-
gression. All analyses adjusted for the randomization
stratum and accounted for clustering of patient data
using generalised estimating equations. Criteria for stat-
istical significance was a p-value of less than 0.05. The
significance of sub-group analyses was tested using
interaction terms. Analyses were performed using SAS
software (SAS institute Inc., Cary, USA).
Results
Recruitment
Of 5601 randomly selected GPs located around
Australia, we contacted 5578 of whom 948 (17.0%)
expressed interest in receiving further information. Of
these, 181 (19.1% or 3% of all GPs approached) con-
sented and completed the academic detailing session
providing baseline data for 593 patients. Two GP
trainees contributing three cases were excluded prior to
randomization (Fig. 2), yielding a final baseline sample
of 179 GPs and 590 cases. One-hundred and 18 GPs re-
ported being in full-time practice (65.9%, including three
missing responses), which is comparable with the na-
tional GP workforce in Australia during 2010/2011 (N =
17,951 out of 27,076 GPs or 66.3% in “full-time service”;
http://www.health.gov.au/internet/main/publishing.nsf/
content/general+practice+statistics-1).
Eighty-nine GPs reporting 298 patient cases were ran-
domly allocated to receive expert decisional support,
while 90 GPs providing data on 292 cases received aca-
demic detailing only (Fig. 2). Of the 590 eligible patients,
48.0% were female (N = 283), while 59.0% (N = 350) were
aged 75 years or older. Half (N = 293, 49.7%) were receiv-
ing anticoagulation at baseline.
Over-two thirds of patients (N = 401, 68.0%) had a
CHADS2 score of 2 or more. Only 51 (8.6%) had a
CHADS2 score of 0. Baseline patient characteristics ap-
peared balanced between groups (Table 1). Of the 179
enrolled GP, 152 completed 497 post-test audits. The
audit post-test completion rate was 84.2% and did not
significantly differ between groups (χ2(1) = 0.47, p = 0.49)
(Fig. 2).
There was evidence that cases lost to follow-up had a
higher stroke risk and were more likely to be receiving
anticoagulation at baseline. Of the 93 cases lost to
follow-up (15.8%), 58.1% (N = 54) received anticoagula-
tion at baseline, compared with 47.5% (N = 236/497) of
those with follow-up data, a near significant difference
(χ2(1) = 3.51, p = 0.06). Mean CHADS2 scores were lower
in patients lost-to-follow-up (Mean = 2.1, SD = 1.3),
compared with those for whom follow-up data were ob-
tained (Mean = 2.3, SD = 1.4), although differences were
not statistically significant (t578 = 1.75, p = 0.08). There
were no significant differences in sex, age group, median
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or mean age or median CHADS2 scores or CHADS2 cat-
egories between patients for whom post-audit data were
and were not collected (p’s > 0.10).
Primary outcome
GPs receiving expert decisional support reported that
52.2% (N = 130) of their patients were anticoagulated at
post-test. By comparison, 47.6% (N = 118) of patents
were anticoagulated at post-test by GPs receiving aca-
demic detailing alone. This difference was not statisti-
cally significant (Adjusted Relative Risk = 1.11, 95% CI =
0.86 to 1.43) (p = 0.42) (Table 2).
Secondary outcomes
Sixty-one percent of patients in both groups received ap-
propriate antithrombotic management at post-test ac-
cording to evidence-based guidelines (Adjusted RR = 1.0,
95% CI = 0.84 to 1.18) (p = 0.97). Similarly, there was no
difference between groups in the proportion of patients
receiving appropriate antithrombotic management in-
corporating quality INR control criteria (40.8% versus
45.0%; Adjusted RR = 0.91, 95% CI = 0.73–1.14, p = 0.43).
Planned sensitivity analyses for these secondary out-
comes including patients younger than 65 years of age
were not carried out given the null findings of the main
analyses. Mean levels of decisional conflict were equiva-
lent between groups (p = 0.44) (Table 2).
Responses to individual items comprising the deci-
sional conflict scale are shown in Fig. 3. For around one-
in-five cases, GPs “strongly agreed” or “agreed” that they
were unsure warfarin was the best treatment for the pa-
tient and whether the benefits of warfarin outweighed
the risks or vice-versa. For one-third of selected cases,
GPs “disagreed” or “strongly disagreed” that it was clear
warfarin was the best treatment for the patient.
Subgroup analyses
Pre-specified subgroup analyses tested differences be-
tween groups on the primary outcome according to
baseline CHADS2 scores (0, 1, or ≥ 2), anticoagulation
use at baseline (yes versus no) and patient sex and age
(< 65 years, 65–74 years, 75–84 years, ≥85 years). There
Fig. 2 CONSORT Flow Diagram, STOP-STROKE in AF study. 2010–2012
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was no evidence that the impact of group allocation on
the primary outcome depended on patient age, sex, base-
line CHADS2 score or baseline use of anticoagulation
(p-valuesinteraction > 0.05).
Amongst patients with available follow-up data, 214
out of 236 (90.7%) receiving anticoagulation at baseline
were still receiving it at post-test, while 11 out of 85
whose GPs reported at baseline their anticoagulation
medication had been discontinued resumed treatment at
post-test (12.9%). Of the 176 patients with no history of
anticoagulation use at baseline, 23 (13.1%) received it at
post-test.
Discussion
Main findings
Specialist feed-back in addition to a self-audit facilitated
by peer-led academic detailing did not increase anti-
coagulant prescribing in Australian general practice. We
Table 1 Baseline comparison of patient characteristics by group, Stop-Stroke in AF study 2010–2012
Variable Academic Detailing+
Expert Decisional Support n (%)
N = 298
Academic
Detailing n (%)
N = 292
Total n (%)
N = 590
Sex
Male 152 (51.0) 155 (53.1) 307 (52.0)
Female 146 (49.0) 137 (46.9) 283 (48.0)
Age Group
< 65 27 (9.1) 30 (10.3) 57 (9.7)
65–74 94 (31.5) 89 (30.5) 183 (31.0)
75–84 117 (39.3) 114 (39.0) 231 (39.2)
85+ 60 (20.1) 59 (20.2) 119 (20.2)
Mean (SD) 76.5 (9.5) 76.5 (9.2) 76.5 (9.4)
Median (IQR)s 77.5 (70–84) 77.0 (70–83) 77 (70–84)
CHADS2 score
0 22 (7.4) 29 (9.9) 51 (8.6)
1 57 (19.1) 71 (24.3) 128 (21.7)
2+ 212 (71.1) 189 (64.7) 401 (68.0)
N/A (Cases with valvular AF) 7 (2.3) 3 (1.0) 10 (1.7)
Mean (SD) 2.4 (1.4) 2.2 (1.4) 2.3 (1.4)
Median (IQR) 2 (1–3) 2 (1–3) 2 (1–3)
Baseline anticoagulation
Yes 153 (51.3) 139 (47.6) 292 (49.5)
Previous Use 46 (15.4) 47 (16.1) 93 (15.8)
No 96 (32.2) 105 (36.0) 201 (34.1)
Missing 3 (1.0) 1 (0.3) 4 (0.7)
Type of antithrombotic
Aspirin 92 (30.9) 102 (34.9) 194 (32.9)
Clopidogrel 12 (4.0) 13 (4.5) 25 (4.2)
Combined Antiplateleta 12 (4.0) 17 (5.8) 29 (4.9)
Anticoagulant+Antiplateletb 13 (4.4) 17 (5.8) 30 (5.1)
Warfarin 125 (41.9) 104 (35.6) 229 (38.8)
Dabigatran 14 (4.7) 16 (5.5) 30 (5.1)
Clexane 1 (0.3) 2 (0.7) 3 (0.5)
None 29 (9.7) 21 (7.2) 50 (8.5)
N/A Not applicable
SD Standard Deviation
IQR Interquartile Range
aIncludes aspirin plus dipyridamole
bFour patients were using dabigatran
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addressed GPs’ concerns about specific cases and de-
tailed medical histories informed specialist feedback.
This is in contrast to traditional methods for providing
feedback using aggregated statistics and benchmark tar-
gets. Yet this novel method was not effective in promot-
ing anticoagulant prescribing.
Comparison with other studies
Audit and feedback and academic detailing do not con-
sistently promote evidence-based practice [13, 14] and
our findings are in step with other evaluations of these
strategies undertaken in a variety of contexts. Results are
also consistent with findings from another study evaluat-
ing a multifaceted intervention for anticoagulation pre-
scribing in AF, incorporating academic detailing and
audit with feedback as we have done [16]. Moreover,
three secondary stroke prevention trials did not report
increased rates of anticoagulant prescribing for patients
in AF in response to structured discharge care plans or
nurse-led care [19, 31, 32].
Frequent feedback, using more than one delivery format,
implementing action plans and providing targets enhance
the effectiveness of audit and feedback [14]. While feed-
back here was delivered twice, verbally and in writing, we
did not include action plans or specific targets and this
may have underpinned the null findings. While feedback
delivered by stroke specialists was hypothesised to be per-
suasive, the influence of experts may have been limited be-
cause they were not otherwise known to GPs nor involved
in the care of their patients. This finding is consistent with
results from another community-based study evaluating
written, evidence-based summaries provided by opinion
leaders, showing no improvement in the management of
heart failure or ischaemic heart disease [33].
Table 2 Comparison of primary and secondary outcomes reported at post-test, by group, Stop Stroke in AF study 2010–2012
Variable Expert Decisional Support n/N
(%)
Academic Detailing alone n/N
(%)
Effect
Estimate
95% CI p-
value
Primary outcomea
Receiving anticoagulant therapy (N = 497) 130/249 (52.2) 118/248 (47.6) RR = 1.11 0.86–
1.43
0.42
Secondary outcomes
Appropriate antithrombotic treatment (N = 443) b 136/223 (61.0) 134/220 (60.9) RR = 1.00 0.85–
1.19
0.97
Appropriate antithrombotic incorporating quality control criteria
(N = 443) b
91/223 (40.8) 99/220 (45.0) RR = 0.91 0.73–
1.14
0.43
Decisional Conflict (N = 497) Mean = 16
95% CI = 15.3–16.7
Mean = 16.6
95% CI = 16.0–17.2
β = −0.50 −1.79-
0.77
0.44
Academic Detailing = Referent group
aIntraclass correlation coefficient for the primary outcome was 0.35
bOutcome was assessed only for patients aged 65 years or older as specified in protocol
Fig. 3 Decisional conflict item scale responses (%), N = 497. The Stop Stroke in AF Study, 2010–2012
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The intervention focussed on GPs while patients were
not engaged. A recent study reported a small (3%) but
significant increase in anticoagulant prescribing attribut-
able to a computerised decision support tool activated
during interactions between physicians and patients [34],
consistent with results from an earlier study employing a
computerised risk assessment tool to guide real-time de-
cision making [35]. In contrast, another recent study
found no effect of an intervention using email notifica-
tions reporting patient-specific stroke risk and guideline
recommendations for antithrombotic treatment [36].
Evidence from other randomised and non-randomised
trials suggests simply having access to support tools,
such as risk calculators, electronically generated feed-
back reports and automated prompts in anticipation of
patient visits does not impact prescribing rates [37–39].
Taken together, findings from this and our own research
imply that interventions delivered outside the context of
the consultation are ineffective, yet providing opportun-
ities for GPs to engage patients in discussions during
real-time decision making may drive changes in pre-
scribing behaviour.
The selection of patients by GPs in whom anticoagula-
tion has been challenging may have made change espe-
cially difficult to achieve as there was no meaningful
differences in anticoagulation rates from baseline to
post-test in either group. The intervention therefore can
be considered ineffective for patients selected in this way
and the results may not generalise to all AF patients in
general practice, for example, patients newly diagnosed
with AF who are naïve to anticoagulants or those with
less challenging needs. The impact of expert decisional
support did not differ according to baseline patient char-
acteristics, including baseline stroke risk. Therefore,
there was no evidence that the impact of the interven-
tion would have differed in patients with varying stroke
risk. We acknowledge, however, that complex needs not
reflected in the CHADS2 score, such as a patient’s social
and psychological circumstances, their cognitive capacity
and adherence to medication may work against efforts
to promote anticoagulation. While we did not systemat-
ically assess such barriers, these factors may have been
relevant for the GPs. Moreover, there was no change in
either group from baseline to post-test.
Implications for current practice
Our study was carried out as guidelines were evolving
away from use of the CHADS2 score to the CHA2DS2-
vasc score for risk stratification although US guidelines
continued to recommend the use of CHADS2 sore in
2012 [40]. We had incorporated the CHA2DS2-vasc
scheme to ensure GPs were aware of impending changes
to local guidelines and feedback from experts also uti-
lised this scheme where relevant. According to current
recommendations [41], more AF patients are identified
as suitable for anticoagulation, including those younger
than 65 years of age. In this study, around 90% of pa-
tients were eligible for anticoagulation using the
CHADS2 risk stratification scheme and therefore would
have also been eligible under the CHA2DS2-vasc scheme.
The main impact of the change in guidelines would have
related to the 57 patients under 65 years of age in our
study.
Antiplatelet medication has been largely superseded
for the management of AF and recommendations now
advise anticoagulation is to be preferred even in rela-
tively low risk patients [42]. Real-world data indicates
that a significant proportion (~ 15%) of patients with AF
are prescribed antiplatelets, [43] and a recent study dem-
onstrates no change in the proportion of patients pre-
scribed aspirin since the change in guidelines [44],
highlighting that current day treatment for AF remains
sub-optimal for a sizeable proportion of patients.
The study was carried out before DOACs became
widely available and at a time when their subsidised re-
lease under Australia’s universal medical insurance
scheme was imminent. Reluctance to prescribe warfarin
may be intransigent. DOACs are perceived to be more
convenient [45] with a proven lower risk of intracerebral
haemorrhage [11] and these characteristics may leverage
wider uptake of anticoagulation. Expert decisional sup-
port may have greater traction in the current post-
DOAC era as DOACs may be an “easier sell” if GPs are
more pre-disposed to using these drugs over warfarin.
However, our results are consistent with several rando-
mised and non-randomised evaluations of implementa-
tion strategies for reducing stroke risk in AF which
mainly report null findings or small differences in the
uptake of anticoagulants in the pre and post-DOAC era
[32, 36–39]. Taken together, these findings indicate that
shifting prescribing practice remains challenging.
The recently published multicentre, multi-national
IMPACT-AF study conducted in low to middle-income
countries, incorporated both patient and GP education
and closely monitored individual patients over a 12-
month period [46]. The study reported a 12% increase in
anticoagulant prescribing over one-year compared with
a 3% change in the usual care control arm. The results
of IMPACT-AF may owe its success to persistent and
sustained contact with both GPs and patients and the
availability of DOACs. However, almost 80% of patients
on anticoagulants were receiving warfarin at post-test,
indicating a continued role for warfarin.
The study findings can be applied to current practice
where warfarin is considered and continues to be used
and, more generally, if the barriers to warfarin use also
impede the uptake of DOACs. In Australia and else-
where, DOAC dispensing has increased concomitantly
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with decreasing warfarin, although warfarin remains
commonly prescribed [44, 47–55], and recent surveys
show that warfarin is favoured amongst a significant
proportion of clinicians [56], particularly for patients in
whom use is established. In Australia, reports indicate
that around one-quarter to one-third of initial anti-
coagulant prescribing is for warfarin [48, 49, 54]. There
is also growing evidence that DOAC prescribing behav-
iour is influenced by the same perceived barriers that
limited the wider use of warfarin indicating that DOACs
do not appear to have bridged the evidence-practice gap
as initially hoped and are subject to the same perceived
limitations of warfarin. Recent studies report a high pro-
portion of uncoagulated patients, for example, 32% [43]
and 57% [52], and evidence also demonstrates that doc-
tors remain cautious about bleeding risks, leading to
non-evidence-based DOAC use. One large multicentre
study of general practice patients showed that 40% of
patients with AF and 40% of those at a high risk of
stroke were not receiving anticoagulation despite trends
towards increasing DOAC use [51]. Moreover, DOACs
have been preferentially prescribed to younger patients,
those with lower bleeding risks, fewer comorbidities
and/or with lower stroke risk [50–53]. This has also
been shown to occur in Australia, where patients with
lower comorbidity burden are preferentially prescribed
higher dose DOACs [57]. The underuse of anticoagula-
tion in patients over the age of 85 remains significant
[43]. In one analysis of over 100,000 anticoagulated AF
patients, DOACs were associated with a higher risk of is-
chaemic stroke and shorter prothrombin time compared
with warfarin use [58], suggesting under-coagulation in
patients using these newer agents. Under-dosing is com-
mon [47, 59–62] and has been associated with an in-
creased risk of thromboembolic events and mortality,
although findings have not been consistent [47, 59–62].
Contraindicated use or use inconsistent with recom-
mendations is another concern [60, 61]. In an Austra-
lian study of AF patients admitted to hospital, 40%
were judged to have been prescribed a DOAC in-
appropriately. Specifically, DOACs were contraindi-
cated in around one-in-eight patients, with both
under-dosing and overdosing reported in patients (~
15 and 10%, respectively) [61].
Moreover, discontinuation of all oral anticoagulants is
prevalent. In a study analysing data from over 45,000
newly-anticoagulated patients in the United States, 50%
receiving Apixaban, 65% receiving Dabigatran, 57% re-
ceiving Rivaroxaban and 71% receiving warfarin discon-
tinued treatment within 1 year of initiating it and no
more than 10% of patients switched to another agent
[63]. In another large-scale study of over 64,000 patients,
only 47% of those taking DOACs adhered to treatment
for more than 80% of the time at a median of 1.1 years
of follow-up, compared with 40% of those taking war-
farin [64] while in another report based on over 62,000
patients newly diagnosed with AF, discontinuation of
DOACs at 3 years was 46% [51]. These results under-
score that stroke risk reduction in AF remans ripe for
knowledge translational activity and, contrary to expec-
tations, barriers to wider and appropriate anticoagulation
persist in contemporary practice.
DOACs were heralded to bridge the evidence-practice
gap in AF management. Wider use of DOACs will in-
crease the absolute numbers of patients who may experi-
ence a bleeding event if such patients would not have
previously been anticoagulated given their risk of an ad-
verse event would have been lower without any anticoa-
gulation. If GPs encounter more patients experiencing
adverse events, this may negatively reinforce their pre-
scribing, resulting in more cautious future use and less
evidence-based prescribing. These altering perceived
risks may potentially impact on prescribing intentions,
motivating GPs to reduce bleeding risk (or an act of
commission) at the expense of reducing stroke risk (an
act of omission) [12]. For these reasons, our results may
inform future studies evaluating strategies to increase
anticoagulation uptake.
Strengths and limitations
The large number of GPs involved in this study is a
strength. Limitations include the unblinded self-reported
outcomes and the 15% attrition rate of participants.
Losses to follow-up were non-differential between
groups and any bias would have likely favoured the
intervention. Further, the three-month scheduled time
between delivery of the intervention and post-test as-
sessment may have limited the opportunities for GPs to
change prescribing practices as recalling patients for a
consultation was not specifically encouraged. Specialists
to whom GPs referred patients may have been predom-
inately responsible for determining treatment and GPs
may have been reluctant to deviate from and contradict
those decisions. The “control group” of the study was an
active arm. Consequently, we do not know whether ei-
ther expert decisional support, academic detailing or
self-audit minimised discontinuation of anticoagulation
compared to usual care. We do not have insights into
GPs’ views about the intervention as we did not conduct
qualitative interviews at the end of the study. Specific-
ally, it would be of interest to understand the reasons
GPs did not change prescribing practice despite expert
recommendations. We did not ask GPs whether they or
another doctor had initiated treatment and do not know
to what extent this contributed to the null findings.
These issues are an important focus for future research.
GPs were advised to select patients for whom manage-
ment presented challenges. This made case selection less
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costly in comparison to an independent audit. Only half of
selected patient cases were receiving anticoagulation, even
though 90% had a risk of stroke justifying anticoagulant
use, characteristics which are consistent with those re-
ported by others [4, 7, 8]. We saw evidence of decisional
conflict with one-in-five GPs indicating difficulties in
weighing up the benefits and risks of anticoagulation with
one-third disagreeing that warfarin was the best choice for
patients. These findings indicate that GPs selected appro-
priate cases for this knowledge translation exercise and
self-audit may be relied upon in future research.
The selection of patients for whom management was
considered challenging may have skewed the cohort to-
wards a group of patients with more complex needs.
More than two-thirds of patients had stroke risk war-
ranting anticoagulation and 70% had a stroke risk
assessed as “high” according to their CHADS2 score
(that is, a score of two or more); fewer than 10% were
deemed at low risk of stroke. The distribution of stroke
risk is skewed towards higher risk compared with regis-
trants in multicentre registries [65], although it is com-
parable to another knowledge translation Australian trial
of AF patients recruited from general practice [35]. An
audit of 82 Australian general practices carried out at
the time this study was conducted reports just over one-
third of patients having high risk of stroke compared
with 70% here, although, like here, fewer than 10% were
considered low risk [66].
The study cohort is best described as one of motivated
volunteers as only 3% of GPs initially contacted eventu-
ally participated in the study. In the context of a rando-
mised evaluation, however, comparisons should be
internally valid. The national scope of the research and
our limited resources precluded more resource intensive
recruitment strategies, such as those involving follow-up
phone calls, site visits and repeated mailings which
would have likely increased participation. The character-
istics of the selected cases are in keeping with previous
studies [4, 7, 8] and the proportion of GPs in full-time
practice was consistent with national GP workforce sta-
tistics. Low participation rates amongst GPs in research
studies is not an isolated experience. In an implementa-
tion trial carried out in the United Kingdom aimed at
improving anticoagulant prescribing in AF, Holt et al.
[37] recruited 8% of 570 general practices invited to par-
ticipate via a mailed letter. Two Australian cluster ran-
domised trials carried out in general practice have
reported a 6% and an 8% participation rate amongst GPs
located within the researchers’ local areas which were
predominately urban [67, 68]. We utilised a study base
of a random sample of GPs which could be expected to
result in a lower participation rate compared with enrol-
ling participants from a registry of self-nominated GPs
interested in research.
To address the challenges in recruiting GPs, we delib-
erately approached a large number of potential partici-
pants and carried out two “Studies Within a Trial”
(SWATs) evaluating various response-aiding strategies
[20] at the time of initial contact. Interest in carrying out
SWATs is gaining momentum to generate high quality
evidence to improve trial administrative processes [69]
and our findings will generate evidence to inform im-
proved recruitment in primary health care implementa-
tion research.
Conclusions
Expert decisional support, delivered in writing, in
addition to one academic detailing session administered
via telephone by a medical peer compared with aca-
demic detailing alone, did not increase anticoagulant
prescribing for patients GPs identified as not receiving
anticoagulation or for whom management was perceived
as challenging. Tested in this way, we found no support
for its usefulness where warfarin was the predominately
available anticoagulant. There may be merit in testing
the effectiveness of specialist support using different
methods of delivery (for example, a more interactive for-
mat), more frequent contact, focussing on newly diag-
nosed patients naïve to anticoagulation or in the context
of increasing anticoagulant use [70], in which evidence-
practice gaps persist [47, 50–53, 59–62, 71]. On the basis
of results reported here, expert decisional support can-
not be recommended to improve anticoagulant prescrib-
ing in patients for whom anticoagulation is challenging.
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